biote Corp. (BTMD)
| Market Cap | 217.28M |
| Revenue (ttm) | 193.06M |
| Net Income (ttm) | 7.19M |
| Shares Out | 36.33M |
| EPS (ttm) | 0.21 |
| PE Ratio | 28.44 |
| Forward PE | 13.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307,692 |
| Open | 6.16 |
| Previous Close | 6.14 |
| Day's Range | 5.94 - 6.25 |
| 52-Week Range | 3.65 - 8.44 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 8.39 (+40.3%) |
| Earnings Date | Nov 12, 2024 |
About BTMD
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BTMD stock is "Strong Buy." The 12-month stock price forecast is $8.39, which is an increase of 40.30% from the latest price.
News
biote Corp. (BTMD) Q3 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD) Q3 2024 Earnings Call November 12, 2024 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Fin...
Biote Reports Third Quarter 2024 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
biote Corp. (BTMD) Q2 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – C...
Biote Reports Second Quarter 2024 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
biote Corp. (BTMD) Q1 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief...
Biote Reports First Quarter 2024 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Announces Definitive Settlement with Founder
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
biote Corp. (BTMD) Q4 2023 Earnings Call Transcript
biote Corp. (BTMD) Q4 2023 Earnings Call Transcript
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today a...
Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Announces $20 Million Share Repurchase Authorization
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote to Purchase Asteria Health
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Biote Names Robert Peterson as Chief Financial Officer
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
biote Should Keep Delivering Strong Growth
biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...
Biote Reports Third Quarter 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial resu...
Biote Reports Second Quarter 2023 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial res...